Last reviewed · How we verify
NCT04791852: FreeDNA-CAV
Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy
trial testing Donor-derived Cell Free DNA in Cardiac Allograft Vasculopathy in 94 participants. Completed in 15 April 2021.
31 January 2021
Quick facts
| Lead sponsor | Puerta de Hierro University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 94 |
| Start date | 10 January 2019 |
| Primary completion | 31 January 2021 |
| Estimated completion | 15 April 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Donor-derived Cell Free DNA
Conditions studied
- Cardiac Allograft Vasculopathy — all drugs for Cardiac Allograft Vasculopathy →
Sponsor
Puerta de Hierro University Hospital
Who can join
Adults 18 to 80, any sex, with Cardiac Allograft Vasculopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Lack of Usefulness of Donor-Derived Cell-Free DNA as a Biomarker for Cardiac Allograft Vasculopathy: A Prospective Study.
Jiménez-Blanco Bravo M, Pérez-Gómez L, Hernández-Pérez FJ, Arellano-Serrano C, et al · · 2022 · cited 11× · PMID 35463750 · DOI 10.3389/fcvm.2022.856600
Verify or expand the search:
- PubMed search for NCT04791852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Allograft Vasculopathy
Currently open trials in the same condition.
- NCT05826444 — Microvascular Cardiac Allograft Vasculopathy Trial · recruiting
Other Puerta de Hierro University Hospital trials
Trials by the same sponsor.
- NCT07509346 — Fecal Microbiota Transplant vs Standard Treatment for Recurrent Non-Obstructive Cholangitis · Phase 2 · not yet recruiting
- NCT07281248 — TRIMODAL PREHABILITATION IN GASTROINTESTINAL CANCER · NA · recruiting
- NCT07008729 — Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world · NA · active not recruiting
- NCT06285760 — Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY) · recruiting
- NCT06293495 — Incidence of Cut-out Using Intramedullary Nails With Double Cephalic Screw vs. Unique in Pertrochanteric Fractures · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04791852 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Puerta de Hierro University Hospital
- Last refreshed: 16 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing